Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OXTR | P30559 | 1/20 | 0.48 |
| ▸ | CCR2 | P41597 | 3/20 | 0.43 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13664907 | 0.84 | OXTR (0.53) | OXTRHSD11B1 | |
| SCHEMBL14112075 | 0.78 | OXTR (0.48) | OXTRHSD11B1 | |
| SCHEMBL8472020 | 0.76 | OXTR (0.57) | OXTRHSD11B1 | |
| SCHEMBL8012161 | 0.75 | MCHR2 (0.58) | OXTR | |
| Hydrochloric Acid SCHEMBL7383656 | 0.74 | OXTR (0.55) | OXTRHSD11B1 | |
| SCHEMBL4233731 | 0.73 | OXTR (0.46) | OXTRHSD11B1 | |
| SCHEMBL15717910 | 0.73 | OXTR (0.51) | OXTRHSD11B1 | |
| SCHEMBL13300484 | 0.72 | MCHR2 (0.57) | OXTRCCR2HSD11B1 | |
| SCHEMBL14671958 | 0.72 | OXTR (0.54) | OXTRHSD11B1 | |
| SCHEMBL12183908 | 0.72 | OXTR (0.54) | OXTRHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1385514-A4 | SPIROINDENE AND SPIROINDANE COMPOUNDS | EURO CELTIQUE SA (LU) | 2005-04-13 | — | — | EP | claimed |
| EP-1385514-A1 | SPIROINDENE AND SPIROINDANE COMPOUNDS | Euro-Celtique S.A. (LU) | 2004-02-04 | — | — | EP | claimed |
| US-20030018041-A1 | Spiroindene and spiroindane compounds | PURDUE PHARMA L.P. | 2003-01-23 | — | — | US | claimed |
| WO-2002085354-A1 | SPIROINDENE AND SPIROINDANE COMPOUNDS | EURO-CELTIQUE S.A. (LU) | 2002-10-31 | — | — | WO | claimed |
| EP-2033644-A1 | Spiroindene and spiroindane compounds | EURO-CELTIQUE S.A. (LU) | 2009-03-11 | — | — | EP | disclosed |
| EP-1385514-A4 | SPIROINDENE AND SPIROINDANE COMPOUNDS | EURO CELTIQUE SA (LU) | 2005-04-13 | — | — | EP | disclosed |
| US-6828440-B2 | Analgesics; side effect reduction | EURO-CELTIQUE, S.A. (LU) | 2004-12-07 | — | — | US | disclosed |
| EP-1385514-A1 | SPIROINDENE AND SPIROINDANE COMPOUNDS | Euro-Celtique S.A. (LU) | 2004-02-04 | — | — | EP | disclosed |
| US-20030018041-A1 | Spiroindene and spiroindane compounds | PURDUE PHARMA L.P. | 2003-01-23 | — | — | US | disclosed |
| WO-2002085354-A1 | SPIROINDENE AND SPIROINDANE COMPOUNDS | EURO-CELTIQUE S.A. (LU) | 2002-10-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030018041-A1 | Spiroindene and spiroindane compounds | NR3C2, REN, NR1I2 | OXTR 959/4885CCR2 334/4885HSD11B1 44/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.